Ilumya (tildrakizumab-asmn) / Sun Pharma, Almirall, Merck (MSD), Hikma, China Medical System - LARVOL DELTA

Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. (PubMed, Cochrane Database Syst Rev) - "Our review shows that, compared to placebo, the biologics infliximab, xeligekimab, bimekizumab, ixekizumab, and risankizumab were the most effective treatments for achieving PASI 90 in people with moderate-to-severe psoriasis, with high-certainty evidence for bimekizumab and moderate-certainty evidence for infliximab, xeligekimab, ixekizumab, and risankizumab. This network meta-analysis evidence is limited to induction therapy (outcomes measured from 8 to 24 weeks after randomisation), and is not sufficient for evaluating longer-term outcomes in this chronic disease. Moreover, we found low numbers of studies for some of the interventions, and the young age (mean 44.4 years) and high level of disease severity (PASI 20.5 at baseline) may not be typical of people seen in daily clinical practice. More randomised trials directly comparing active agents are needed, and these should include systematic subgroup analyses (sex, age, ethnicity, comorbidities, psoriatic arthritis)...."

Clinical • Journal • Retrospective data • Review • Dermatology • Immunology • Inflammatory Arthritis • Oncology • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • IL12A • IL17A

A systematic review of the role of interleukin inhibitors in lichen planus: therapeutic and paradoxical effects. (PubMed, Inflammopharmacology) - "IL inhibitors demonstrate both treatment and paradoxical effects on LP. Further research is needed to elucidate the impact of these agents on the pathophysiology of LP."

Journal • Review • Atopic Dermatitis • Dermatitis • Dermatology • Dermatopathology • Immunology • Lichen Planus • Oncology • Psoriasis • CXCL8 • IFNA1 • IFNG • IL10 • IL12A • IL17A • IL18 • IL21 • IL22 • IL23A • IL4 • IL5 • IL6 • IL9 • TNFA

Introduction of Biopharmaceuticals in Europe: A Cross-Sectional Study of Early Diffusion Patterns and Data Availability. (PubMed, BioDrugs) - "This study revealed a substantial variation between European countries and regions in the early diffusion of biopharmaceuticals and the availability of data to monitor their use. The reasons behind these patterns require further investigation to support European countries in optimizing the use of biopharmaceuticals to reach an equitable and cost-effective use of medicines across Europe."

Journal • Observational data

Time to Onset of Action for Biologics and Targeted Treatments in Psoriasis: Systematic Targeted Literature Review and Network Meta-Analysis. (PubMed, Dermatol Ther (Heidelb)) - "IL-17 inhibitors, followed by IL-23 inhibitors, have the most rapid TOA among PsO biologics evaluated; any differences in onset of action between specific agents within the same drug class are not statistically or clinically significant. These analyses will allow clinicians to make more informed treatment decisions for their patients."

Journal • Retrospective data • Dermatology • Immunology • Psoriasis • IL12A • IL17A • IL23A

Monitoring of nail psoriasis with optical coherence tomography under treatment with Tildrakizumab for 52 weeks (EADV 2025) - No abstract available

Dermatology • Immunology • Psoriasis

Monitoring of nail psoriasis with optical coherence tomography under treatment with Tildrakizumab for 52 weeks (EADV 2025) - No abstract available

Dermatology • Immunology • Psoriasis

Tildrakizumab significantly improves genital psoriasis in an interim data of the phase IV ZODIPSO study until 52 weeks (EADV 2025) - No abstract available

P4 data • Dermatology • Immunology • Psoriasis

Safety, Immunogenicity, and Efficacy of Tildrakizumab in Patients With Chronic Plaque Psoriasis: Final Results From the reSURFACE 1 and reSURFACE 2 Long-Term Extension Studies (EADV 2025) - No abstract available

Clinical • Dermatology • Immunology • Psoriasis

Tildrakizumab significantly improves scalp psoriasis in an interim data of the phase IV ZODIPSO study until 52 weeks (EADV 2025) - No abstract available

P4 data • Dermatology • Immunology • Psoriasis

Tildrakizumab significantly improves nail psoriasis in an interim data of the phase IV ZODIPSO study until 52 weeks (EADV 2025) - No abstract available

P4 data • Dermatology • Immunology • Psoriasis

Psychological Well-being of Moderate-to-Severe Plaque Psoriasis Patients Treated with Tildrakizumab in Clinical Practice in Italy: study design and main objectives of the phase IV BLUE Study (EADV 2025) - No abstract available

Clinical • P4 data • Dermatology • Immunology • Psoriasis

Immune checkpoint inhibitor–induced psoriasis successfully treated with tildrakizumab in an oncologic patient (EADV 2025) - No abstract available

Checkpoint inhibition • Clinical • Dermatology • Immunology • Oncology • Psoriasis

Tildrakizumab: a single-center retrospective study of effectiveness and safety in real clinical practice in patients with psoriasis and psoriatic arthritis (EADV 2025) - No abstract available

Retrospective data • Dermatology • Immunology • Inflammatory Arthritis • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies

Psycholag in moderate-to-severe psoriasis: insights from the POSITIVE study on psychological well-being and treatment with tildrakizumab (EADV 2025) - No abstract available

Dermatology • Immunology • Psoriasis

Psychological Well-being of Moderate-to-Severe Plaque Psoriasis Patients Treated with Tildrakizumab in Clinical Practice in Italy: 28 week interim data from the phase IV BLUE Study (EADV 2025) - No abstract available

Clinical • P4 data • Dermatology • Immunology • Psoriasis

Tildrakizumab in Real-World Chinese Psoriasis: Efficacy-Safety Profiles from a 28-Week Prospective Cohort with Geriatric and Metabolic Syndrome Stratification (EADV 2025) - No abstract available

Clinical • Real-world • Real-world evidence • Dermatology • Immunology • Metabolic Disorders • Psoriasis

Needs and treatment expectations of elderly patients with moderate to severe psoriasis treated with tildrakizumab in routine clinical practice: week 28 interim results on patients' needs and wellbeing (EADV 2025) - No abstract available

Clinical • Dermatology • Immunology • Psoriasis

Effectiveness and treatment satisfaction with Tildrakizumab 200 mg in routine clinical practice: 28 weeks interim results from the TIL-TWO study (EADV 2025) - No abstract available

Clinical • Dermatology • Dermatopathology • Immunology • Psoriasis

Assessing tildrakizumab's effectiveness in psoriasis patients with baseline joint pain: interim results from the POSITIVE study (EADV 2025) - No abstract available

Clinical • Dermatology • Immunology • Musculoskeletal Diseases • Musculoskeletal Pain • Orthopedics • Pain • Psoriasis

Efficacy of Tildrakizumab in Psoriasis patients - data from a real-world study over three years (EADV 2025) - No abstract available

Clinical • Real-world • Real-world evidence • Dermatology • Immunology • Psoriasis

Safety of Tildrakizumab in Psoriasis patients - data from a real-world study over three years (EADV 2025) - No abstract available

Clinical • Real-world • Real-world evidence • Dermatology • Immunology • Psoriasis

The Economic Value of Tildrakizumab Treatment in Patients with Moderate-to-Severe Plaque Psoriasis: A Norwegian Perspective (EADV 2025) - No abstract available

Clinical • Dermatology • Immunology • Psoriasis

Effectiveness and safety of tildrakizumab in the treatment of genital psoriasis in Austria, Switzerland, and the Czech Republic (CZATCH-Genital-PsO): 28-week interim results (EADV 2025) - No abstract available

Clinical • Dermatology • Immunology • Psoriasis

Effectiveness of tildrakizumab in improving itching in Austrian patients with plaque psoriasis (EADV 2025) - No abstract available

Clinical • Dermatology • Immunology • Pruritus • Psoriasis

Real-world experience with tildrakizumab in moderate-to-severe psoriasis (EADV 2025) - No abstract available

Clinical • Real-world • Real-world evidence • Dermatology • Immunology • Psoriasis